Williams Zander, Hull James H, Ge Yueqi, Ming Jo, Roberts Cara, Rhamie Serena, Patel Pujan H
Department of Respiratory Medicine, Royal Brompton Hospital, London, UK.
Institute of Sport, Exercise and Health (ISEH), Division of Surgery and Interventional Science, University College London, London, UK.
ERJ Open Res. 2023 Dec 27;9(6). doi: 10.1183/23120541.00635-2023. eCollection 2023 Nov.
Domiciliary spirometry (DS) is a novel tool that is widely employed in the assessment of respiratory disease. We assessed real-world feasibility, effectiveness and value of a physiologist-led home spirometry programme in patients with treatment-refractory severe asthma.
Patients were referred and provided with a hand-held DS device. Patients completed baseline measurements in a physiologist-led virtual clinic and were instructed to provide further values during any periods of respiratory symptoms. Outcome measures included prevalence of new obstructed events, DS adherence and uptake of this approach.
112 patients were enrolled from November 2020 to January 2023. 102 individuals, mean±sd age 44±13 years (86% female) with median (IQR) forced expiratory volume in 1 s % predicted 88% (77-97%), successfully recorded baseline spirometry values. During follow-up (24 months), 11 (11%) were identified with new obstructive spirometry and were subsequently able to be commenced on biologic therapy. Patient engagement was poor with median (IQR) of 4 (2-6) attempts of contact made before baseline values were recorded, and 2 (1-3) attempts required to record technically acceptable values. Continued DS use was suboptimal; 34% failed to use their device after baseline and only 10% continued at the end of the study period. The cost of DS measurements was greater than a single hospital-based visit but enables multiple event capture.
Overall, DS measurement uptake was poor, with a minority of patients continuing to use the device at the end of the study period. However, for those that engage, DS provides an alternative approach to traditional hospital-based spirometry measurements that can alter clinical management.
家庭肺功能仪(DS)是一种广泛应用于呼吸系统疾病评估的新型工具。我们评估了由生理学家主导的家庭肺功能仪项目在治疗难治性重度哮喘患者中的实际可行性、有效性和价值。
患者被转诊并配备了手持式DS设备。患者在由生理学家主导的虚拟诊所完成基线测量,并被指示在任何呼吸道症状期间提供进一步的测量值。结果指标包括新的阻塞性事件的发生率、DS的依从性以及这种方法的采用情况。
2020年11月至2023年1月共纳入112例患者。102例患者成功记录了基线肺功能测量值,平均年龄±标准差为44±13岁(86%为女性),1秒用力呼气容积占预计值的中位数(IQR)为88%(77 - 97%)。在随访期间(24个月),11例(11%)被发现有新的阻塞性肺功能异常,随后开始接受生物治疗。患者参与度较低,在记录基线值之前平均(IQR)进行了4次(2 - 6次)联系尝试,记录技术上可接受的值需要2次(1 - 3次)尝试。DS的持续使用情况不理想;34%的患者在基线后未使用设备,在研究期结束时只有10%的患者仍在继续使用。DS测量的成本高于单次医院就诊,但能够捕获多个事件。
总体而言,DS测量的采用情况不佳,在研究期结束时只有少数患者继续使用该设备。然而,对于那些参与的患者,DS为传统的基于医院的肺功能测量提供了一种替代方法,可以改变临床管理。